Astrazeneca Could Easily Acquire Gilead Sciences
AZN) could easily acquire Gilead Sciences, Inc. (NASDAQ:GILD)” data-reactid=”12″>AstraZeneca plc (NYSE:AZN) could easily acquire Gilead Sciences, Inc. (NASDAQ:GILD)
Q2 2020 hedge fund letters, conferences and more” data-reactid=”43″>Q2 2020 hedge fund letters, conferences and more
Value To Almost 1.8x Gilead Sciences’…The Market’s Invisible Hand May Be Tempting AZN To Outright Acquire GILD…Rather Than The Prior Merger Chatter.” data-reactid=”50″>…Lifting AstraZeneca’s Enterprise Value To Almost 1.8x Gilead Sciences’…The Market’s Invisible Hand May Be Tempting AZN To Outright Acquire GILD…Rather Than The Prior Merger Chatter.
Worthwhile To Note…Also…That While Gilead Apparently Rebuffed AstraZeneca’s Overtures Earlier This Year …Current CEO’s…Pascal Soriot At AstraZeneca + Daniel O’Day At Gilead…Simultaneously…Worked Together At Swiss Drug Giant Roche.
So…Likely…The Discussions Were More Than Plain Cordial + Superficial.
And Make No Mistake…Being Acquainted With Each Other = A Big Help In Corporate Courting Matters.
Streams…And Hence…The Share Price.” data-reactid=”54″>Further…A Deal To Sell Gilead Could Bail Out O’Day’s Brief And…Thus Far…Disappointing Legacy At Gilead…Initiated March 2019…Partially…With The Hope Of Inspiring New Product Revenue Streams…And Hence…The Share Price.
Thus Far…Neither Have Occurred…Despite Covid Driven Hopes For Several Months…Earlier This Year…As Shares Continue To Dismally Lag Its Peers …While Wall Street Seems To Be Tremendously Unimpressed With Both O’Day’s Execution And His Strategic Vision.
Plus GILD’s Relative Share Price…Vis-A-Vis the XLV Healthcare Index [see below] Further Validates…Even Pre-Dating O’Day’s Arrival…Despite Being A Strong Cash Flow Generator With A Bulletproof Balance Sheet And A 4.1% Dividend Yield.
And GILD Shareholders…Frustrated With The Stock’s Dramatic Under-Performance For Almost 4 Full Years [Pre + Post O’Day]…Would Likely Encourage + Rubberstamp Any Reasonable Offer From AZN.
For It’s Part…AZN Folds Several Solid Franchise Hepatitis + HIV Drugs Into Its Existing Portfolio…Structured As A Capital Accretive Deal Without Much Financial Risk Given GILD’S Investment Grade Credit Ratings.
Jacob Wolinsky” data-reactid=”83″>By Jacob Wolinsky
